Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CTMX |
---|---|---|
09:32 ET | 1254 | 1.18 |
09:39 ET | 2875 | 1.185 |
09:41 ET | 1498 | 1.175 |
09:48 ET | 10634 | 1.16 |
09:50 ET | 365 | 1.1684 |
09:54 ET | 300 | 1.165 |
09:56 ET | 200 | 1.165 |
09:57 ET | 183 | 1.1678 |
09:59 ET | 900 | 1.16 |
10:01 ET | 200 | 1.165 |
10:03 ET | 400 | 1.16 |
10:12 ET | 4224 | 1.1581 |
10:14 ET | 5200 | 1.155 |
10:17 ET | 600 | 1.155 |
10:19 ET | 600 | 1.155 |
10:24 ET | 400 | 1.155 |
10:26 ET | 600 | 1.155 |
10:30 ET | 8000 | 1.15 |
10:32 ET | 100 | 1.1596 |
10:33 ET | 462 | 1.1515 |
10:35 ET | 27965 | 1.155 |
10:42 ET | 7759 | 1.1599 |
10:44 ET | 400 | 1.15 |
10:46 ET | 614 | 1.1599 |
10:48 ET | 2580 | 1.155 |
10:50 ET | 1250 | 1.155 |
10:51 ET | 2000 | 1.156 |
10:53 ET | 725 | 1.155 |
10:55 ET | 1500 | 1.1562 |
10:57 ET | 500 | 1.15 |
11:00 ET | 800 | 1.155 |
11:02 ET | 400 | 1.155 |
11:04 ET | 600 | 1.155 |
11:06 ET | 1000 | 1.1565 |
11:08 ET | 4633 | 1.155 |
11:09 ET | 900 | 1.15 |
11:11 ET | 500 | 1.16 |
11:13 ET | 500 | 1.15 |
11:15 ET | 1000 | 1.15 |
11:18 ET | 100 | 1.15 |
11:22 ET | 100 | 1.155 |
11:24 ET | 151 | 1.1572 |
11:26 ET | 600 | 1.155 |
11:27 ET | 228 | 1.155 |
11:31 ET | 100 | 1.155 |
11:36 ET | 950 | 1.1583 |
11:38 ET | 125 | 1.158833 |
11:42 ET | 100 | 1.155 |
11:44 ET | 100 | 1.155 |
11:45 ET | 2264 | 1.153 |
11:47 ET | 139 | 1.1583 |
11:54 ET | 1000 | 1.1501 |
11:56 ET | 100 | 1.15 |
12:00 ET | 4052 | 1.1575 |
12:07 ET | 100 | 1.15 |
12:09 ET | 200 | 1.155 |
12:12 ET | 100 | 1.155 |
12:16 ET | 1500 | 1.16 |
12:18 ET | 300 | 1.1574 |
12:20 ET | 100 | 1.15 |
12:27 ET | 9069 | 1.15 |
12:34 ET | 1007 | 1.155 |
12:41 ET | 300 | 1.1503 |
12:45 ET | 2998 | 1.15 |
12:50 ET | 1100 | 1.15 |
12:54 ET | 200 | 1.1574 |
12:57 ET | 4030 | 1.155 |
12:59 ET | 10100 | 1.1502 |
01:03 ET | 300 | 1.155 |
01:06 ET | 700 | 1.15 |
01:08 ET | 100 | 1.155 |
01:10 ET | 200 | 1.155 |
01:14 ET | 2652 | 1.15 |
01:15 ET | 4415 | 1.15 |
01:17 ET | 100 | 1.15 |
01:19 ET | 100 | 1.15 |
01:21 ET | 14407 | 1.135 |
01:24 ET | 1170 | 1.14 |
01:26 ET | 2800 | 1.14 |
01:28 ET | 3651 | 1.1417 |
01:30 ET | 2900 | 1.14 |
01:32 ET | 200 | 1.1431 |
01:35 ET | 354 | 1.1475 |
01:37 ET | 3893 | 1.145 |
01:39 ET | 1600 | 1.145 |
01:42 ET | 850 | 1.1401 |
01:44 ET | 100 | 1.145 |
01:46 ET | 930 | 1.15 |
01:48 ET | 400 | 1.145 |
01:50 ET | 100 | 1.15 |
01:55 ET | 500 | 1.145 |
01:57 ET | 593 | 1.1496 |
02:02 ET | 1498 | 1.1499 |
02:06 ET | 100 | 1.1425 |
02:08 ET | 3870 | 1.155 |
02:09 ET | 100 | 1.155 |
02:15 ET | 5400 | 1.155 |
02:26 ET | 12100 | 1.155 |
02:27 ET | 100 | 1.155 |
02:33 ET | 30298 | 1.165 |
02:36 ET | 2600 | 1.165 |
02:38 ET | 200 | 1.165 |
02:42 ET | 24790 | 1.15 |
02:45 ET | 100 | 1.155 |
02:51 ET | 100 | 1.15 |
02:56 ET | 100 | 1.155 |
02:58 ET | 800 | 1.1556 |
03:03 ET | 3400 | 1.150275 |
03:05 ET | 100 | 1.15 |
03:07 ET | 400 | 1.155 |
03:12 ET | 100 | 1.15 |
03:14 ET | 100 | 1.155 |
03:18 ET | 100 | 1.15 |
03:20 ET | 800 | 1.155 |
03:21 ET | 10400 | 1.155 |
03:23 ET | 200 | 1.155 |
03:27 ET | 100 | 1.155 |
03:30 ET | 400 | 1.155 |
03:34 ET | 100 | 1.155 |
03:38 ET | 200 | 1.155 |
03:39 ET | 1100 | 1.15 |
03:45 ET | 1700 | 1.155 |
03:48 ET | 100 | 1.155 |
03:50 ET | 6116 | 1.155 |
03:52 ET | 200 | 1.155 |
03:54 ET | 500 | 1.155 |
03:56 ET | 1400 | 1.155 |
03:57 ET | 21341 | 1.15 |
03:59 ET | 63617 | 1.15 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
CytomX Therapeutics Inc | 92.2M | 8.4x | --- |
Spero Therapeutics Inc | 72.4M | 4.1x | --- |
2Seventy Bio Inc | 243.1M | -1.5x | --- |
Fortress Biotech Inc | 38.7M | -0.4x | --- |
Cannabis Bioscience International Holdings Inc | 7.3M | 0.0x | --- |
MDxHealth SA | 98.4M | -1.3x | --- |
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $92.2M |
---|---|
Revenue (TTM) | $119.6M |
Shares Outstanding | 78.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.03 |
EPS | $0.14 |
Book Value | $-0.70 |
P/E Ratio | 8.4x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | 7.1x |
Operating Margin | 4.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.